Compare Cronos Group Inc (CRON) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Medpace Holdings Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 14.3× Cronos Group Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Medpace Holdings Inc for 14 Days on average.
| CRON | MEDP | |
|---|---|---|
Market Cap | $1.18B | $16.82B |
Volume | 968,037 | 223,093 |
Sector | Health | Health |
52-Week High | $3.55 | $630.19 |
52-Week Low | $2.30 | $393.42 |
Typical Hold Time | 22 Days | 14 Days |
Enterprise Value | $387.62M | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with 58% YoY revenue growth, and maintains a robust balance sheet with $827 million in cash and no debt. Recent investor day highlighted expansion in Canada and international markets.
Outlook is mixed; profitability improved with net income margin turning positive in 2026 forecasts, but high EV/EBITDA of 43 suggests premium valuation. Risks include execution of growth plans and cannabis sector volatility. Analyst consensus is cautious with 60% hold ratings.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
